/biz/ - Business & Finance

>>11942941
VTGN is making a drug called AV-101 to treat depression and neuropathic pain
AV-101 acts on the same neurological pathway in the same way as ketamine (they're both NMDA antagonists), and there's significant scientific literature, as well as increasing use in clinical settings, supporting the efficacy of ketamine in treating both of those things
The advantages AV-101 has over ketamine is that it's orally bioavailable (you can take it as pills instead of having to inject it), which makes it a lot more likely for doctors to prescribe it, and it has fewer long-term side effects and safety concerns than ketamine
Its performance in clinical trials and the fact that it's been fast tracked by the FDA twice indicate that it's a promising drug that can potentially solve the problems of a drug that's been proven to be very effective but has several disadvantages hindering its adoption as a more widespread means of treatment

It's a small-cap biotech stock, so it's naturally very volatile and will dip and rise wildly on relatively low volume, in addition to being vulnerable to short term manipulation
Ultimately, the winning strategy is to be patient and hold as long as the fundamentals are there


http://www.pharmatimes.com/magazine/2018/november_2018/company_focus_vistagen#.W84iOIsVBuU.twitter
https://ir.vistagen.com/press-releases/detail/79
https://www.streetinsider.com/Corporate+News/VistaGen+Therapeutics+%28VTGN%29+Granted+FDA+Fast+Track+Designation+for+Development+of+AV-101+as+a+Non-Opioid+Treatment+for+Neuropathic+Pain/14669763.html
https://www.tipranks.com/stocks/vtgn/price-target

>>11913048
No problem, I don't mind helping
I've just been kind of pissy in general today, everyone has moments of weakness